Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$119.10 USD

119.10
722,614

+0.60 (0.51%)

Updated Sep 4, 2024 02:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs

by Kinjel Shah

FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.

Novartis' (NVS) Cosentyx Gets FDA Nod for New Indication

by Zacks Equity Research

Novartis' (NVS) Cosentyx wins FDA approval for a fourth indication ??? active non-radiographic axial spondyloarthritis (nr-axSpA).

Lilly Gains as Verzenio Meets Early Breast Cancer Study Goal

by Zacks Equity Research

Lilly's (LLY) phase III study on Verzenio in HR+, HER2- early breast cancer met its primary endpoint of invasive disease-free survival.

Bayer Initiates a Phase III Study in Heart Failure Patients

by Zacks Equity Research

Bayer (BAYRY) initiates a phase III study to evaluate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients with a left ventricular ejection fraction.

Kinjel Shah headshot

FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus

by Kinjel Shah

The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.

Novartis' (NVS) Beovu Gets FDA Approval for Label Update

by Zacks Equity Research

Novartis' (NVS) ophthalmology drug, Beovu, gets update for safety information regarding retinal vasculitis and retinal vascular occlusion.

The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Mastercard, Novartis, Boeing Company, Sanofi and Honeywell International

Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD

by Zacks Equity Research

Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.

Bayer (BAYRY) Submits Applications for Heart Failure Drug

by Zacks Equity Research

Bayer (BAYRY) seeks approval of chronic heart failure drug, vericiguat, in the EU and Japan.

Alnylam Reports Positive Phase III Results on Lumasarin

by Zacks Equity Research

Alnylam (ALNY) reports positive phase III results from the ILLUMINATE-A study on lumasiran.

Here's Why You Should Retain Genpact (G) in Your Portfolio

by Zacks Equity Research

Genpact (G) is currently benefiting from a strong customer base and accretive acquisitions.

Sheraz Mian headshot

Top Stock Reports for Mastercard, Novartis & Boeing

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Novartis (NVS) and Boeing Company (BA).

Novartis' Asthma Treatment Meets Primary Endpoint in Phase III

by Zacks Equity Research

Novartis (NVS) announces positive results from a late-stage study on Enerzair Breezhaler in patients with asthma.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals

by Kinjel Shah

Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.

Novartis (NVS) Announces Positive Data From Cosentyx Study

by Zacks Equity Research

Novartis (NVS) reports encouraging data from the phase III PREVENT study evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis.

Novartis' sBLA for Ofatumumab Gets Extended Review From FDA

by Zacks Equity Research

The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.

AbbVie Seeks US and EU Nods for Rinvoq for Psoriatic Arthritis

by Zacks Equity Research

AbbVie (ABBV) files applications to the FDA and the EMA seeking approval for a new indication of Rinvoq, active psoriatic arthritis. The drug is already marketed to treat rheumatoid arthritis.

Novartis' (NVS) Breast Cancer Drug Gets Positive CHMP Opinion

by Zacks Equity Research

Novartis (NVS) gets positive CHMP opinion for breast cancer drug, Piqray. The company also announces other pipeline updates.

Pfizer's Ibrance Fails in Phase III Early Breast Cancer Study

by Zacks Equity Research

Pfizer's (PFE) phase III PALLAS study compared Ibrance plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy in HR+, HER2- early breast cancer.

Zacks.com headshot

PhaseBio Gets FDA Nod to Begin Study for Coronavirus Treatment

by Zacks.com

PhaseBio (PHAS) receives clearance of IND application from the FDA to evaluate PB1046 as a treatment for hospitalized COVID-19 patients.

Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA

by Zacks Equity Research

Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.

Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA

by Zacks Equity Research

Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.

Deciphera (DCPH) Secures Early FDA Nod for GIST Drug Qinlock

by Zacks Equity Research

The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.

Acceleron (XLRN) Q1 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Acceleron (XLRN) posts a wider-than-expected Q1 loss due to increased operating expenses. The company misses on revenues as well.

Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Puma Biotech's (PBYI) loss and revenues better estimates in the first quarter of 2020.